Himadri Speciality Chemical Ltd

Himadri Speciality Chemical Ltd announced record-breaking financial results for the quarter ended June 30, 2026. Consolidated revenue reached ₹1,432 Cr, a 28% increase year-on-year. EBITDA stood at ₹313 Cr, up 33% YoY, with Profit After Tax (PAT) at ₹228 Cr, a 27% increase YoY. The company highlighted strong performance driven by product mix, ramp-up in speciality materials, and execution of its diversification strategy. Key growth initiatives include developing indigenous Carbon Nanotube (CNT) technology with a planned 200 MTPA facility and expanding into Super Speciality Carbon Black (SSCB). The New Energy Materials business is a focus, with advancements in anode and LFP cathode materials, targeting significant capacity expansions. Strategic investments in Sicona and IBC further bolster its position in the battery materials ecosystem.

Himadri Speciality Chemical Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, issued by ICRA Limited. The report confirms that the utilization of proceeds from the Preferential Issue of Warrants, amounting to ₹341.8172 Crores, is in line with the stated objects of the issue. There has been no deviation observed in the utilization of funds. The report is prepared as per SEBI regulations and does not constitute an audit or assurance on the quality or outcome of the spending.

Himadri Speciality Chemical Ltd announced board approval for significant capital expenditures across multiple projects. The company will invest ₹128 Crores to expand Anthraquinone and Carbazole manufacturing capacity, ₹70 Crores for India's first Carbon Nano Tubes (CNT) facility, and ₹170 Crores for Super Speciality Carbon Black production. These expansions aim to enhance production of high-value specialty products and reduce import dependency, aligning with the 'Atmanirbhar Bharat' vision. The board also approved the unaudited financial results for the quarter ended 30 June 2026.

Himadri Speciality Chemical Ltd announced board approval for significant capital expenditures. This includes an additional ₹128 Crores to expand Anthraquinone and Carbazole manufacturing capacity from 2600 MTPA to 5300 MTPA, with phased commissioning by Q2FY27 and Q2FY28. The company also approved ₹70 Crores for India's first Carbon Nano Tubes (CNT) manufacturing facility in West Bengal, with a capacity of 200 MTPA, expected by Q4FY27. Furthermore, a capex of ₹170 Crores is allocated for Super Speciality Carbon Black (SSCB) manufacturing with a capacity of 6,000 MTPA, to be commissioned by Q4FY28. These expansions are primarily funded through internal accruals and align with the company's strategy to focus on high-value products and reduce import dependency.

Himadri Speciality Chemical Ltd has announced the issuance and allotment of Commercial Paper (CP) amounting to ₹150 Crore. The Finance and Management Committee of the Board of Directors approved the allotment of 3,000 units of CP, each with a face value of ₹5,00,000/-, aggregating to ₹150 Crore. The instrument has a tenure of 90 days, with a coupon rate of 6.60% per annum, payable upfront. The CP is unsecured, will be listed on BSE Ltd, and is issued in favor of Kotak Mahindra Bank. The maturity date for this issuance is October 7, 2026.

Himadri Speciality Chemical Ltd has announced that its Board of Directors will convene on July 15, 2026. The primary agenda for this meeting is to consider and approve the Un-Audited Standalone and Consolidated Financial Results for the quarter ending June 30, 2026. Additionally, the company has informed about the reopening of the trading window for its securities, which will be effective 48 hours after the declaration of these financial results.

Himadri Speciality Chemical Ltd announced the allotment of 19,000 equity shares of Re.1 each to eligible employees under the "Himadri Employee Stock Option Plan 2016". The exercise price per share was ₹140, with a premium of ₹139 per share. This allotment increases the company's issued and paid-up capital to ₹50,45,60,599, comprising 50,45,60,599 equity shares. The new shares rank pari-passu with existing shares. The filing also provides details as per SEBI (Share based Employee Benefits and Sweat Equity) Regulations, 2021.

Mahabir Prasad Agarwal and a group of Persons Acting in Concert (PACs) have disclosed a change in their shareholding in Himadri Speciality Chemical Limited. The group has sold a net of 99,00,000 shares, reducing their total holding from 8.21% to 6.25% of the company's total share capital. The transactions occurred through open market and inter-se transfers between March 19, 2025, and July 1, 2026. The total diluted share capital of the company remains largely stable.

Himadri Speciality Chemical Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with the company's code of conduct and SEBI regulations regarding insider trading. The window will be shut from July 1, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter ending June 30, 2026. The company will reopen the trading window after the results are officially announced to the stock exchanges. This measure is standard practice to prevent potential insider trading during sensitive financial reporting periods.

Himadri Speciality Chemical Ltd has announced the opening of a new office in Mumbai, Maharashtra. This strategic move aims to bolster the company's presence and enhance its business operations within the Western Region of India. The new office is located at Fleet House, 1st Floor, Andheri - Kurla Rd, Gamdevi, Marol, Andheri East, Mumbai, Maharashtra 400059, and commenced operations on June 20, 2026. The company has also made this information available on its official website.